Skip to main content
Home > Week in Review > Clinical Results

Chronological Index of : Clinical Results

 Current Issue
  • Biosimilar etanercept: Phase III data

    Novartis AG (NYSE:NVS; SIX:NOVN), Basel, Switzerland Product: Biosimilar etanercept (GP2015) Business: Autoimmune Molecular target: Tumor necrosis factor (TNF) alpha Description: Biosimilar of etanercept, a recombinant …

    Published on 7/18/2016
  • Bococizumab: Phase III data

    Pfizer Inc. (NYSE:PFE), New York, N.Y. Product: Bococizumab (PF-4950615, RN316, PF-04950615) Business: Endocrine/Metabolic Molecular target: Proprotein convertase subtilisin/kexin type 9 (PCSK9) Description: Human mAb …

    Published on 7/18/2016
  • Bococizumab: Phase III data

    Pfizer Inc. (NYSE:PFE), New York, N.Y. Product: Bococizumab (PF-4950615, RN316, PF-04950615) Business: Endocrine/Metabolic Molecular target: Proprotein convertase subtilisin/kexin type 9 (PCSK9) Description: Human mAb …

    Published on 7/18/2016
  • BPX-01: Phase IIa data

    BioPharmX Corp. (NYSE-M:BPMX), Menlo Park, Calif. Product: BPX-01 Business: Dermatology Molecular target: NA Description: Topical formulation of minocycline, a semisynthetic derivative of tetracycline Indication: Treat …

    Published on 7/18/2016
  • CHS-1701: Phase I data

    Coherus BioSciences Inc. (NASDAQ:CHRS), Redwood City, Calif. Product: CHS-1701 Business: Hematology Molecular target: Granulocyte colony-stimulating factor (G-CSF) (CSF3) Description: Biosimilar of pegfilgrastim, a …

    Published on 7/18/2016
  • Cobiprostone: Development discontinued

    Sucampo Pharmaceuticals Inc. (NASDAQ:SCMP), Bethesda, Md. Product: Cobiprostone (SPI-8811) (formerly RU-8811) Business: Other Molecular target: Chloride channel 2 (CLCN2) (ClC-2) Description: Prostone chloride channel 2…

    Published on 7/18/2016
  • Ganaxolone: Phase II data

    Marinus Pharmaceuticals Inc. (NASDAQ:MRNS), Radnor, Pa. Product: Ganaxolone (CCD-1042) Business: Neurology Molecular target: GABA A receptor Description: Synthetic analog of the endogenous neurosteroid allopregnanolone,…

    Published on 7/18/2016
  • Lidocaine vaginal gel: Phase I data

    Juniper Pharmaceuticals Inc. (NASDAQ:JNP), Boston, Mass. Product: Lidocaine vaginal gel (COL-1077) Business: Neurology Molecular target: Sodium channel Description: Lidocaine bioadhesive 10% vaginal gel Indication: …

    Published on 7/18/2016
  • MYK-461: Phase I data

    MyoKardia Inc. (NASDAQ:MYOK), San Francisco, Calif. Sanofi (Euronext:SAN; NYSE:SNY), Paris, France Product: MYK-461 Business: Cardiovascular Molecular target: Cardiac myosin Description: Small molecule allosteric …

    Published on 7/18/2016
  • NBTXR3: Additional Phase I/II data

    Nanobiotix S.A. (Euronext:NANO), Paris, France PharmaEngine Inc. (TPEx:4162), Taipei, Taiwan Product: NBTXR3, PEP503 Business: Cancer Molecular target: DNA Description: Crystalline nanoparticles of hafnium oxide …

    Published on 7/18/2016
  • Piclidenoson: Phase II data

    Can-Fite BioPharma Ltd. (Tel Aviv:CFBI; NYSE-M:CANF), Petah Tikva, Israel Product: Piclidenoson (IB-MECA) (CF101) Business: Ophthalmic Molecular target: Adenosine A3 receptor (ADORA3) Description: Adenosine A3 receptor…

    Published on 7/18/2016
  • PnuBioVax: Phase I data

    ImmunoBiology Ltd., Cambridge, U.K. Product: PnuBioVax Business: Infectious Molecular target: NA Description: Vaccine containing heat shock proteins and multiple antigens produced by a genetically modified form of …

    Published on 7/18/2016
  • ProCervix: Additional Phase II data

    Genticel S.A. (Euronext:GTCL), Labege, France Product: ProCervix (GTL001) Business: Cancer Molecular target: Human papillomavirus (HPV) antigens Description: Bivalent therapeutic cancer vaccine against HPV types 16 and …

    Published on 7/18/2016
  • PXL770: Phase I data

    Poxel S.A. (Euronext:POXEL), Lyon, France Product: PXL770 Business: Endocrine/Metabolic Molecular target: AMP-activated protein kinase (AMPK) Description: Direct activator of AMP-activated protein kinase (AMPK) …

    Published on 7/18/2016
  • RG-101: Additional Phase II data

    Regulus Therapeutics Inc. (NASDAQ:RGLS), San Diego, Calif. Product: RG-101, Anti-miR-122 Business: Infectious Molecular target: MicroRNA-122 (miR-122) Description: GalNAc-conjugated antagonist targeting miR-122 …

    Published on 7/18/2016
  • RhGUS: Phase III data

    Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), Novato, Calif. Product: RhGUS (UX003) Business: Endocrine/Metabolic Molecular target: NA Description: Recombinant human glucuronidase beta (rhGUS) Indication: Treat …

    Published on 7/18/2016
  • SAGE-547: Phase II data

    Sage Therapeutics Inc. (NASDAQ:SAGE), Cambridge, Mass. Product: SAGE-547 Business: Neurology Molecular target: GABA A receptor Description: Positive allosteric modulator (PAM) of GABA A receptor Indication: Treat severe…

    Published on 7/18/2016
  • Stivarga regorafenib: Additional Phase III data

    Bayer AG (Xetra:BAYN), Leverkusen, Germany Product: Stivarga regorafenib (fluoro-sorafenib) (BAY 73-4506) Business: Cancer Molecular target: Vascular endothelial growth factor (VEGF) receptor 2 (VEGFR-2) (KDR/Flk-1); …

    Published on 7/18/2016
  • Sutent sunitinib: Phase III data

    Pfizer Inc. (NYSE:PFE), New York, N.Y. Product: Sutent sunitinib Business: Cancer Molecular target: Platelet derived growth factor receptor (PDGFR); Vascular endothelial growth factor (VEGF) receptor Description: Small …

    Published on 7/18/2016
  • Topsalysin: Additional Phase IIa data

    Sophiris Bio Inc. (NASDAQ:SPHS), La Jolla, Calif. Kissei Pharmaceutical Co. Ltd. (Tokyo:4547), Nagano, Japan Product: Topsalysin (PORxin) (PRX302) (formerly PSA-PAH1) Business: Cancer Molecular target: …

    Published on 7/18/2016
  • Triple-bead MAS: Phase III data

    Shire plc (LSE:SHP; NASDAQ:SHPG), Dublin, Ireland Product: Triple-bead MAS (SHP465) (formerly SPD465) Business: Neurology Molecular target: Not available Description: Three-component, extended-release, single-entity …

    Published on 7/18/2016
  • VY-AADC01: Interim Phase Ib data

    Voyager Therapeutics Inc. (NASDAQ:VYGR), Cambridge, Mass. Product: VY-AADC01 Business: Neurology Molecular target: Dopa decarboxylase (DDC) (AADC) Description: Adeno-associated virus (AAV) serotype 2 capsid and a …

    Published on 7/18/2016
  • ZYN002: Phase I data

    Zynerba Pharmaceuticals Inc. (NASDAQ:ZYNE), Radnor, Pa. Product: ZYN002 Business: Neurology Molecular target: NA Description: Synthetic cannabidiol (CBD) formulated as a transdermal gel Indication: Treat epilepsy …

    Published on 7/18/2016
  • AB001: Phase II data

    Frontier Biotechnologies Co. Ltd., Nanjing, China Product: AB001 Business: Neurology Molecular target: NA Description: Topical NSAID patch Indication: Treat chronic lower back pain Endpoint: Change in pain intensity …

    Published on 7/11/2016
  • Albuvirtide: Interim Phase III data

    Frontier Biotechnologies Co. Ltd., Nanjing, China Product: Albuvirtide Business: Infectious Molecular target: HIV gp41 Description: Long-acting viral entry inhibitor targeting HIV gp41 Indication: Treat HIV-1 infection …

    Published on 7/11/2016

< Previous   1  2  3  4  5  6  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993